Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia

Raúl Gómez, Raul Gómez, Gómez R, Antonio Abad, Abad A, Francisco Delgado, Delgado F, Silvia Tamarit, Tamarit S, Carlos Simón, António Pellicer, Antonio Pellicer
Fertility and sterility · 2010 · vol. 95(3) , pp. 882–888.e1 · doi:10.1016/j.fertnstert.2010.10.024 · PMID:21055747 · W2032337615
article OA: closed CC0 ⤵ 60 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study investigated how treatment with the dopamine agonist quinagolide affects endometriotic lesions in patients experiencing hyperprolactinemia alongside endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo assess whether dopamine receptor 2 agonists reduced the size of peritoneal lesions in women with endometriosis and elucidate whether affectation of vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2)-dependent angiogenesis was mediating the observed effects.DesignProof-of-concept study.SettingUniversity hospital and a university-affiliated private IVF research center.Patient(s)Hyperprolactinemic patients (n = 9) with endometriosis requiring a first surgical intervention (L1) and benefiting from a second-look laparoscopy (L2) were evaluated.Intervention(s)During L1, four to six peritoneal red lesions were identified. One-half of the lesions were removed and the remaining one-half were labeled with silk knot sutures. After L1, quinagolide was administered in a titrated manner (25-75 μg/d) for 18-20 weeks. During L2, the remaining lesions were surgically excised.Main outcome measure(s)Both L1 and L2 were video recorded to compare the effects of quinagolide treatment on lesion size. Lesions removed at L1 and L2 were compared by means of: 1) histologic analysis; 2) immunohistochemical quantitative analysis of angiogenesis; and 3) quantitative fluorescence polymerase chain reaction array analysis of 84 chemokines and pro-/antiangiogenic molecules.Result(s)Quinagolide induced a 69.5% reduction in the size of the lesions, with 35% vanishing completely. Histologic analysis showed tissue degeneration, which was supported by down-regulation of VEGF/VEGFR2, three proangiogenic cytokines (CCL2, RUNX1, and AGGF1) and plasminogen activator inhibitor (PAI) 1, a potent inhibitor of fibrinolysis in the L2 lesions.Conclusion(s)By interfering with angiogenesis, enhancing fibrinolysis, and reducing inflammation, quinagolide reduces or eliminates peritoneal endometriotic lesions in women with endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Aminoquinolines Dopamine Agonists Endometriosis Hyperprolactinemia Hyperprolactinemia Aminoquinolines Aminoquinolines Dopamine Agonists Dopamine Agonists Endometriosis Endometriosis Endometriosis Endometrium Endometrium Endometrium Endometrium Female Gene Expression Profiling Humans Hyperprolactinemia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (42)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:00.782903+00:00
License: CC0 · commercial use OK